AngioDynamics (ANGO) PT, Estimates Cut at Piper Jaffray Following 'Tough' Qtr
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Canaccord Genuity are Buyers of AngioDynamics (ANGO) on Weakness
April 10, 2015 9:55 AM EDTCanaccord Genuity analyst Jason Mills lowered his price target on AngioDynamics (NASDAQ: ANGO) to $20.00 (from $22.00) following soft Q3 results but maintained a Buy rating. The firm would be buyers on weakness.
Mills commented, "We would be buyers on weakness associated with soft FQ3 results and downward revision to guidance. On the heels of several consecutive quarters of solid execution, including expanding top-line growth and GM, a confluence of factors negatively impacted the business in F3Q, driving revenue below expectations. A few of these challenges were out of ANGOs control (negative foreign... More
AngioDynamics (ANGO) Misses Q3 EPS by 4c, Lowers FY15 Guidance
April 9, 2015 4:04 PM EDTAngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.12, $0.04 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $86.6 million versus the consensus estimate of $89.8 million.
AngioDynamics sees FY2015 EPS of $0.57-$0.60, may not compare to the consensus of $0.68. AngioDynamics sees FY2015... More
